ACTR-32. NRG ONCOLOGY RTOG 1205: RANDOMIZED PHASE II TRIAL OF CONCURRENT BEVACIZUMAB AND RE-IRRADIATION VS. BEVACIZUMAB ALONE AS TREATMENT FOR RECURRENT GLIOBLASTOMA Article

Tsien, Christina, Pugh, Stephanie, Dicker, adam et al. (2019). ACTR-32. NRG ONCOLOGY RTOG 1205: RANDOMIZED PHASE II TRIAL OF CONCURRENT BEVACIZUMAB AND RE-IRRADIATION VS. BEVACIZUMAB ALONE AS TREATMENT FOR RECURRENT GLIOBLASTOMA . NEURO-ONCOLOGY, 21(Supplement_6), vi20-vi20. 10.1093/neuonc/noz175.075

cited authors

  • Tsien, Christina; Pugh, Stephanie; Dicker, adam; Raizer, Jeffrey; Matuszak, Martha; Lallana, Enrico; Huang, Jiayi; algan, ozer; Taylor, Nicholas; Portelance, Lorraine; Villano, John; Hamm, John T; Oh, Kevin S; Ali, Arif N; Kim, Michelle; Lindhorst, Scott; Mehta, Minesh

authors

publication date

  • November 11, 2019

published in

keywords

  • 32 Biomedical and Clinical Sciences
  • 3202 Clinical Sciences
  • 3211 Oncology and Carcinogenesis
  • 6.1 Pharmaceuticals
  • Brain Cancer
  • Brain Disorders
  • Cancer
  • Clinical Research
  • Clinical Trials and Supportive Activities
  • Health Disparities
  • Minority Health
  • Neurosciences
  • Rare Diseases

Digital Object Identifier (DOI)

publisher

  • Oxford University Press (OUP)

start page

  • vi20

end page

  • vi20

volume

  • 21

issue

  • Supplement_6